CINFA LAUNCHES OLMEDINE HCT IN UNITED ARAB EMIRATES, OFFERING AND EFFECTIVE SOLUTION FOR THE TREATMENT OF HIGH BLOOD PRESSURE
- Around 28.8% of adults in the UAE have high blood pressure, according to the Ministry of Health of the United Arab Emirates. The increase of this disease could potentially be due to the growth of the obesity, inactivity or the over consume of salt.1
- Cinfa is committed to cardiovascular health and specifically to the control of high blood pressure and, therefore, works hard on innovation with the aim of offering health solutions to patients.
- Dr. Alicia López de Ocariz, Corporate Medical Director at Cinfa Group, has emphasized the importance of preventing cardiovascular diseases, and highlighted that “80% of cardiovascular diseases are preventable, therefore, it is essential that society is aware that their lifestyle affects their health”.
The European pharmaceutical laboratory Cinfa has launched its new product Olmedine HCT to control high blood pressure.
Hypertension (HTN) is one of the non-communicable diseases whose prevalence is increasing in both developed and developing countries2. Cinfa has made this launch in response to it in the Middle East, a region where this disease has become a major public health challenge, according to the ministry of health of the United Arab Emirates.
The new product is composed of Olmesartan medoxomil, Amlodipine (as amlodipine besylate) and Hydrochlorothiazide, three molecules available in different doses (20mg/12.5mg/5mg), (40mg/10mg/12.5mg), (40mg/10mg/25mg), (40mg/5mg/12.5mg), (40mg/5mg/25mg).
Dr. Alicia López de Ocariz, Corporate Medical Director at Cinfa Group, has emphasized the importance of preventing cardiovascular diseases, and highlighted that “80% of cardiovascular diseases are preventable, therefore, it is essential that society is aware that their lifestyle affects their health”.
And added that, “five major risk factors for cardiovascular diseases are high blood pressure, high levels of low-density lipoprotein [LDL] cholesterol, low levels of high-density lipoprotein [HDL] cholesterol, high fasting glucose level and smoking. Family history is an independent risk factor, particularly among younger individuals with a family history of premature disease”.
USE OF OLMEDINE HCT
Olmedine HCT is used as a treatment for adult patients whose blood pressure is not sufficiently controlled with the combination of two of these three molecules. In addition, it is used in patients who are already taking a combination of olmesartan medoxomil and hydrochlorothiazide together with amlodipine but not in one single tablet. Use of Olmedine HCT is a rational approach for achieving optimal therapeutic benefits while minimizing pill-burden, specially important in chronic diseases as hypertension. Greater convenience with decreased pill-burden leads to improved adherence, resulting in superior clinical outcomes and greater cost-effectiveness. The different and multiple dosages of Omedine HCT allows dosage flexibility and dose titration Composition of the medicine
This medication is compound by three active substances:
- Olmesartan medoxomil: is an angiotensin-II receptor antagonist. which blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II.
- Amlodipine (as amlodipine besilate): is a calcium channel blocker. This substance directly acts on vascular smooth muscle to produce peripheral arterial vasodilation reducing peripheral vascular resistance and blood pressure.
- Hydrochlorothiazide: is a thiazide diuretic. The hypotensive response is mediated by a reduction in plasma volume and cardiac output.
REFERENCES:
1Prevalence, awareness, treatment and control of hypertension in four Middle East countries https://mohap.gov.ae/en/media-center/news/9/6/2022/mohap-to-intensify-efforts-to-reduce-hypertension-prevalence-in-the-uae
2Systematic review and meta-analysis: Prevalence of hypertension among adolescents in the Arab countries https://www.sciencedirect.com/science/article/abs/pii/S0882596322000641